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ABSTRACT
The hematological changes associated with septrin administration in humans were investigated. One hundred (100)
male patients (aged 18-40 years) who were placed on the therapeutic dose of septrin were divided into four groups
based on the prescribed duration of their septrin intake. Twenty (20) healthy males served as the control. At the end
of the treatment period, blood was obtained from each subject for the estimation of blood parameters following
standard procedures. The results showed that the packed cell volume (PCV), total white blood cell count (WBC),
neutrophils and platelets were significantly decreased (p<0.05), especially after 7-10 days of septrin administration,
compared to the control values. On the other hand, the reticulocytes, lymphocytes, eosinophils and prothrombin time
(PT) showed significant increases (p<0.05), compared to the value for the control. The observed changes in blood
parameters in this study were all duration-dependent. It is concluded that septrin administration can cause alterations
in blood parameters, and these duration-dependent changes should be put into consideration when recommending its
intake.
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INTRODUCTION
Septrin is a brand name for a combination of antibiotics called cotrimoxazole. The drug is composed of two active
principles: trimethaprim and sulphamethoxadole, and used to prevent/treat pneumocystis carinii pneumonia, PCP
(Jaffe et al., 1983).
Sulphamethoxadole is a structural analogue of p-amino benzoic acid (PABA), which is essential and required for the
synthesis of folic acid- precursors of deoxyribonucleic acid (DNA) and RNA in both bacteria and mammals, with
the later obtaining their folate from the diet and not from PABA. Sulphamethoxadole works by competing with
PABA for the enzyme dihydropteroate synthetase (Howland and Mycek, 2007). In this way, it inhibits the growth of
bacteria (i.e. it is bacteriostatic).
On the other hand, ‘Trimethoprim’ interferes with the ability of bacteria to metabolize folinic acid, thus exerting a
bacteriostatic activity. Trimethoprim is a folate antagonist,  which inhibits the conversion of dihydrofolate to the
desired  form  (tetrahydrofolate)  by  the  key  enzyme  dihydrofolate  reductase,  which  is  extremely  sensitive  to
trimethaprim (Roach and Scherer, 2000).
Sulphamethoxadole  and  trimethaprim  therefore,  affects  two  stages  in  the  same  metabolic  pathway  for  folate
synthesis in bacteria (in the form of a double barrel attack). Septrin is a widely used effective antibacterial drug by
adults and children. The indications for septrin usage include urinary tract infections (Stamm and Hoosten, 1993),
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typhoid, bacterial diarrhea (Wormser et al., 1982), dysentery and PCP (Tripathi et al., 2001). However, in spite of its
efficacy, septrin administration has been associated with side effects that include anemia and other changes in some
hematological  parameters.  Reported  side  effects  of  sulphamethoxadole  include  hemopoietic  disturbance  (bone
marrow depression), hemolytic anemia in patients with glucose phosphate dehydrogenase deficiency (Champe  et
al., 2000),  granulocytopenia  and  thrombocytopenia  (Howland  and  Mycek,  2007).  On  its  part,  trimethaprim
administration can produce the effects  of folic acid deficiency, marked by megaloblastic  anemia, leukemia and
granulocytopenia,  especially  in  pregnant  patients  and  those  on  poor  diet  (Rang  et  al,  2000).  This  study  was
therefore, embarked upon to investigate the pathophysiology of some of the treatment-induced changes in blood
parameters following septrin administration.
MATERIAL AND METHODS
Study population: This study was carried out at the Irrua Specialist Hospital Irrua, Edo State, Nigeria (a tertiary
health institution used as a Teaching Hospital for the College of Medicine of Ambrose Alli University, Ekpoma, Edo
State). Out and in-patients who attended the hospital during the periods of study were randomly selected for this
investigation. The control group was randomly selected from staff of the hospital.
Ethical  consideration:  A written  approval  by the Ethics  Committee of  the Teaching  Hospital  was sought  and
obtained for this study. Secondly, an informed consent by all the subjects was obtained before the start of the study.
Study design:  A total  of  120 males,  aged  between 18 and 40 years,  were  used for  this study. The test  group
consisted of one hundred (100) male out-patients and in-patients,  who were placed on the therapeutic  doses of
septrin. The control was made up of 20 apparently healthy males, aged between 18 and 40 years, who were not on
any medications during the period of the study. The test group was divided into four categories of 25 persons each,
according to the duration of septrin administration. The categories were: 3-6 days, 7-10 days, 11-13 days, and above
14 days.
Collection of Blood Sample:  Venous blood was obtained from each subject and dispensed into specimen bottles
that contained 0.2mls of 10% EDTA. The contents were well mixed immediately, labeled and used to carry out the
following investigations: packed cell volume (PCV), total white blood cell (WBC) count, platelet count, reticulocyte
count,  differential  WBC  count,  and  prothrombin  time  (using  plasma  from  the  blood  sample,  immediately,  to
determine the time it took for clot to form).
Sample Analyses:  The packed cell volume (PCV), white blood cells count (WBC), differential WBC count and
Platelet count (PC) were estimated by the method of Dacie and Lewis (1990). For the prothrombin time, an aliquot
(0.1ml) of the blood sample from each subject was dropped individually into test tubes numbered 1-10. Thereafter,
0.1ml of commercially prepared control sample was dropped into tube number 11.  All the tubes were warmed at
37oC for 3mins (tube 11 for 5mins). Subsequently, 0.2ml of prothrombin reagent was added to each test tube; and the
clotting time was observed and recorded for each tube. Standard laboratory procedures were followed for all the
experiments in the study.
Statistical  Analysis:  The  result  of  the  experiment  was  statistically  analyzed  using  SPSS windows  version  16
software. The results are presented as means ± SEM. Student’s t-test was used to test for significance. P values of
<0.05 were considered as significant.
RESULTS
The results of the investigation show that septrin administration caused increases in some and decreases in other
hematological parameters. Specifically, PCV was significantly (p<0.05) decreased, especially, in the subjects that
were on septrin administration for 10-13days and above. The mean PCV values range from 40.00±3.32% in 3-6 days
of treatment to 35.0±4.10% in above 14 days, compared with the control value of 40.0±3.32%. The mean total white
blood cell count was significantly reduced, in a duration-dependent manner, from 5.50±1.71UI in 3-6 days of septrin
administration  to  3.90±0.45UI  in  above  14  days  of  intake,  when  compared  with  the  mean  control  value  of
6.0±1.51UI.
The mean platelet count also significantly reduced, as treatment duration increased, from 176.80±19.39UI after 3-6
days to 97.20±13.60 after 14 days, compared with the mean control value of 201.90±26.30. The neutrophils number
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decreased, as duration of administration increased, from mean value of 61.0±7.64UI after 3-6 days, to 40.0±8.36UI
after 14 days; while the mean control value was 62.0±8.40UI. This represents a maximum percentage decrease of
35.5% in more than 14 days of treatment, compared to the mean control value.
The hematological parameters that were significantly increased due to septrin administration include the following:
reticulocyte  count,  lymphocytes,  eosinophils,  and  prothrombin  time.  The  mean  reticulocyte  count  increased
significantly (p<0.05), from 0.80±0.33 (or 25.0%) after 3-6 days of treatment to 1.0±0.56 (or 40.0%) after more than
14 days of treatment, compared to the mean control value of 0.60±0.17. The increase in the lymphocytes in blood
ranged from 39.0±7.32 after 3-6 days of septrin administration to 57.20±8.26 after more than 14 days of treatment,
compared  to  the  mean control  lymphocyte  value of  38.0±0.37.  This  shows significant  increases  of  25.5% and
38.6%, after 11-13 days and above 14 days of septrin administration, respectively. The eosinophil in the treated
subjects increased significantly by 42.3% (0.26±0.45) after  3-6 days  and by 88.4% (1.3±2.23) after  14 days  of
treatment, compared to the mean control eosinophil value of 0.15±0.37. 
The results of the basophils (0.10±0.31) and monocytes (0.10±0.31) in the blood of the treated subjects did not
change  during  the  treatment  period,  when  compared  to  the  respective  mean  control  values.  The  result  of  the
prothrombin  time  showed  significant  increases  which  ranged  from12.60±1.96  after  3-6  days  of  treatment,  to
16.80±1.40 after over 14 days of treatment, compared to the mean control value of 11.35±1.31. This represent a
range of 12.70% - 30 40% increase in prothrombin time, compared to the control value. 
Table 1. Mean values and percentage changes in blood parameters in human subjects during Septrin
administration
Durations of Septrin Administration
 Index                  Control                 3 – 6 Days             7 – 10 Days           11 – 13 Days         Above 14 Days
 PCV               42.0±3.14 40.0±3.32 40.0±2.32 37.0±3.68* 35.0±4.10*
(% change)                                (-4.76) (-4.76) (-11.90) (-16.70)
WBC                 6.0±1.51 5.5±1.71 5.8±0.84 4.10±0.18* 3.90±0.45* 
(% change) (-8.30) (-3.30) (-31.70) (-35.00)
Platelet              201.9±46.30 176.8±19.39 167.6±27.17 108.0±8.37* 97.2±13.60*     
(% change) (-12.43) (-16.99) (-46.50) (-51.90)
Reticulocyte       0.60±0.17 0.80±0.32 0.70±.24 0.90±0.38* 1.0±0.56*
(% change) (+25.00) (+14.30) (+33.30) (+40.00)
Neutrophil          62.0±8.40 61.0±7.64 60.0±7.90 47.0±6.65* 40.0±8.36*
(% change) (-1.61) (-3.23) (-24.20) (-35.50)
Lymphocyte       38.0±0.41 39.0±7.32 39.0±7.32 51.0±8.76* 57.2±8.26*
(% change) (+2.60) (+2.60) (+25.50) (+38.60) 
Eosinophil          0.15±0.37 0.26±0.45* 0.26±0.45* 1.14±0.75* 1.30±2.23*
(% change) (+42.30) (+42.30) (+86.00) (+88.40)
Basophil              0.10±0.31 0.10±0.31 0.10±0.31 0.10±0.31 0.10±0.31
Monocyte            0.10±0.32 0.10±0.32 0.10±0.32 0.10±0.32 0.10±0.32
Prothr. Time        11.35±1.31 12.60±1.96 14.40±1.98* 16.80±1.31* 16.80±1.40* 
 (% change)                                      (+12.70)                (+23.60)                (+30.40)                (+30.40)
Data represented as Mean ±SEM ;  *Significantly different from control, (p<0.05); - represent reduction/decrease; +
represents addition/increase 
DISCUSSION 
The  findings  of  this  study  demonstrated  that  septrin  administration  caused  variations  in  some  hematological
parameters  and  the  observed  variations  become more  obvious  with  increase  in  the  duration  of  treatment.  The
observed duration dependent decrease in the PCV of all the treatment groups is thought to be due to inhibition of
folate metabolism by the drug. These results conform with previous reports by Christie (1999) that the adverse
effects of septrin administration are related to the duration of treatment, and not always due to the administered
dosage.
Interestingly, the total white blood cell (WBC) count decreased significantly, especially after 10 days of  septrin
administration at mean of 4.10±0.18x10-4, compared to the mean control value of 6.0±1.51x x10-4.  This duration-
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dependent reduction in WBC count coincided with the observed pattern of decrease in the neutrophils in the present
study. One can deduce that the observed reduction in neutrophils by 24.20% after 10 days of treatment, contributed
to the observed 31.7% decrease in total white blood cell count at the same duration of septrin administration. This
result supports the earlier report by Bloom and Small (1998) that prolonged septrin administration could lead to
leucopenia in human subjects.
The significant duration-dependent decrease in platelet count may not be unconnected with the observed significant
increase in the prothrombin time, since the prothrombin time is a function and product of the platelet number and
aggregation activity (Fox, 1999). Schoring (1996) observed that septrin acts as haptens that bind platelets during
their activity, but the decrease in platelet number in this study may have mitigated this property. The decrease in
platelet number may also result from reduction in blood cell formation due to septrin-induced depression to bone
marrow activity (Patrono, 1999). This effect on platelet may suggest that prolonged administration of septrin might
indeed lead to development of thrombocytopenia – the effect of low platelet count. Septrin is believed to be an
antagonist  to  folic  acid  metabolism,  and  this  may  predispose  septrin  users  to  folic  acid  deficiency,  and  thus,
compromise the use of folic acid in WBC production, and may consequently lead to leucopenia (Bloom and Small,
1998). 
Similarly,  the  significant  duration-dependent  decrease  in  neutrophil  number  may indeed  be  responsible  for  the
observed decrease in total white blood cell count obtained in this study since it represent a major component of the
WBC. On the contrary, reticulocyte number increased significantly in a duration-dependent manner after 11-13 days
of treatment and this may represent hemopoietic response of the bone marrow to the observed reduction in packed
cell volume reported earlier in the present study. 
Furthermore,  platelet  count  was  significantly  decreased  in  a  duration-dependent  manner;  this  outcome may be
responsible for the observed significant increase in the prothrombin time recorded in this study. The 25.5% increased
in lymphocyte number after 11-13 days may be a response to compensate for the decreases in neutrophils and white
blood cells observed earlier in the present study, which may have given rise to the recruitment of lymphocytes which
may cause acute lymphocytosis.  The highest increase in blood cells in this study however, was observed in the
eosinophils number which demonstrated significant rapid increase of 42.3% after just 3-6 days of administration,
compared to the control value. This high increase in eosinophil count may have significantly contributed to the
equally significant increase in the total WBC count.
Finally, prothrombin time (PT) was significantly increased in the subjects in a duration-dependent  manner. The
observed increase in PT may be related to the duration-dependent decrease in platelet count since the rate of blood
coagulation is a function of platelet count and aggregation activity. It may also be a reflection of treatment-induced
deficiency in either factors VII, X, V, or prothrombin (Ezeilo, 2009). Further studies are however, required to verify
this possibility.
Conclusion
The  therapeutic  administration  of  septrin  can  cause  a  significant  duration-dependent  variation  in  blood  cell
parameters,  and  these  unlisted  side  effects  should  be  adequately  put  into  consideration  during its  prescription.
Further investigations are recommended so as to further evaluate the long term impact of these treatment-induced
alterations in blood cell parameters.
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